Cargando…
Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis or Bladder Pain Syndrome (IC/BPS) is a heterogeneous condition characterized by elevated levels of inflammatory cytokines, IL-1β, IL-6, IL-8, IL-10, TNF-α, and is associated with debilitating symptoms of pelvic pain and frequent urination. A standard of care for IC/BPS has not...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145543/ https://www.ncbi.nlm.nih.gov/pubmed/33923265 http://dx.doi.org/10.3390/jpm11050342 |
_version_ | 1783697199153020928 |
---|---|
author | Maharaj, Dipnarine Srinivasan, Gayathri Makepeace, Sarah Hickey, Christopher J. Gouvea, Jacqueline |
author_facet | Maharaj, Dipnarine Srinivasan, Gayathri Makepeace, Sarah Hickey, Christopher J. Gouvea, Jacqueline |
author_sort | Maharaj, Dipnarine |
collection | PubMed |
description | Interstitial Cystitis or Bladder Pain Syndrome (IC/BPS) is a heterogeneous condition characterized by elevated levels of inflammatory cytokines, IL-1β, IL-6, IL-8, IL-10, TNF-α, and is associated with debilitating symptoms of pelvic pain and frequent urination. A standard of care for IC/BPS has not been established, and most patients must undergo a series of different treatment options, with potential for severe adverse events. Here, we report a patient with a 26-year history of IC/BPS following treatment with multiple therapies, including low doses of etodolac, amitriptyline and gabapentin, which she was unable to tolerate because of adverse effects, including headaches, blurred vision and cognitive impairment. The patient achieved a complete clinical remission with minimal adverse events after 16 cycles of N-acetylcysteine (NAC) intravenous (IV) infusions over a period of 5 months, and pro-inflammatory cytokine levels were reduced when compared to measurements taken at presentation. Personalized low dose NAC IV infusion therapy represents an effective, safe, anti-inflammatory therapy administered in the outpatient setting for IC/BPS, and warrants further investigation. |
format | Online Article Text |
id | pubmed-8145543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81455432021-05-26 Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome Maharaj, Dipnarine Srinivasan, Gayathri Makepeace, Sarah Hickey, Christopher J. Gouvea, Jacqueline J Pers Med Case Report Interstitial Cystitis or Bladder Pain Syndrome (IC/BPS) is a heterogeneous condition characterized by elevated levels of inflammatory cytokines, IL-1β, IL-6, IL-8, IL-10, TNF-α, and is associated with debilitating symptoms of pelvic pain and frequent urination. A standard of care for IC/BPS has not been established, and most patients must undergo a series of different treatment options, with potential for severe adverse events. Here, we report a patient with a 26-year history of IC/BPS following treatment with multiple therapies, including low doses of etodolac, amitriptyline and gabapentin, which she was unable to tolerate because of adverse effects, including headaches, blurred vision and cognitive impairment. The patient achieved a complete clinical remission with minimal adverse events after 16 cycles of N-acetylcysteine (NAC) intravenous (IV) infusions over a period of 5 months, and pro-inflammatory cytokine levels were reduced when compared to measurements taken at presentation. Personalized low dose NAC IV infusion therapy represents an effective, safe, anti-inflammatory therapy administered in the outpatient setting for IC/BPS, and warrants further investigation. MDPI 2021-04-24 /pmc/articles/PMC8145543/ /pubmed/33923265 http://dx.doi.org/10.3390/jpm11050342 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Maharaj, Dipnarine Srinivasan, Gayathri Makepeace, Sarah Hickey, Christopher J. Gouvea, Jacqueline Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome |
title | Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome |
title_full | Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome |
title_fullStr | Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome |
title_full_unstemmed | Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome |
title_short | Clinical Remission Using Personalized Low-Dose Intravenous Infusions of N-acetylcysteine with Minimal Toxicities for Interstitial Cystitis/Bladder Pain Syndrome |
title_sort | clinical remission using personalized low-dose intravenous infusions of n-acetylcysteine with minimal toxicities for interstitial cystitis/bladder pain syndrome |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145543/ https://www.ncbi.nlm.nih.gov/pubmed/33923265 http://dx.doi.org/10.3390/jpm11050342 |
work_keys_str_mv | AT maharajdipnarine clinicalremissionusingpersonalizedlowdoseintravenousinfusionsofnacetylcysteinewithminimaltoxicitiesforinterstitialcystitisbladderpainsyndrome AT srinivasangayathri clinicalremissionusingpersonalizedlowdoseintravenousinfusionsofnacetylcysteinewithminimaltoxicitiesforinterstitialcystitisbladderpainsyndrome AT makepeacesarah clinicalremissionusingpersonalizedlowdoseintravenousinfusionsofnacetylcysteinewithminimaltoxicitiesforinterstitialcystitisbladderpainsyndrome AT hickeychristopherj clinicalremissionusingpersonalizedlowdoseintravenousinfusionsofnacetylcysteinewithminimaltoxicitiesforinterstitialcystitisbladderpainsyndrome AT gouveajacqueline clinicalremissionusingpersonalizedlowdoseintravenousinfusionsofnacetylcysteinewithminimaltoxicitiesforinterstitialcystitisbladderpainsyndrome |